دورية أكاديمية
Dupilumab: Mechanism of action, clinical, and translational science.
| العنوان: | Dupilumab: Mechanism of action, clinical, and translational science. |
|---|---|
| المؤلفون: | McCann MR; Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA., Kosloski MP; Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA., Xu C; Sanofi, Bridgewater, New Jersey, USA., Davis JD; Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA., Kamal MA; Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA. |
| المصدر: | Clinical and translational science [Clin Transl Sci] 2024 Aug; Vol. 17 (8), pp. e13899. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: WileyBlackwell Pub Country of Publication: United States NLM ID: 101474067 Publication Model: Print Cited Medium: Internet ISSN: 1752-8062 (Electronic) Linking ISSN: 17528054 NLM ISO Abbreviation: Clin Transl Sci Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Malden, MA : WileyBlackwell Pub., 2008- |
| مواضيع طبية MeSH: | Antibodies, Monoclonal, Humanized*/therapeutic use , Antibodies, Monoclonal, Humanized*/pharmacology , Interleukin-4 Receptor alpha Subunit*/antagonists & inhibitors , Interleukin-4 Receptor alpha Subunit*/metabolism , Dermatitis, Atopic*/drug therapy , Dermatitis, Atopic*/immunology , Interleukin-13*/antagonists & inhibitors , Interleukin-13*/metabolism , Interleukin-13*/immunology , Translational Research, Biomedical*, Humans ; Interleukin-4/antagonists & inhibitors ; Interleukin-4/metabolism ; Asthma/drug therapy ; Asthma/immunology ; Eosinophilic Esophagitis/drug therapy ; Eosinophilic Esophagitis/immunology ; Signal Transduction/drug effects ; Nasal Polyps/drug therapy ; Nasal Polyps/immunology ; Prurigo/drug therapy ; Translational Science, Biomedical ; Sinusitis/drug therapy ; Sinusitis/immunology |
| مستخلص: | Allergic disease prevalence has increased globally with the subset of type 2 inflammatory diseases playing a substantial role. Type 2 inflammatory diseases may differ in clinical presentation, but they exhibit shared pathophysiology that is targeted by the unique pharmacology of dupilumab. Dupilumab binds to the interleukin (IL)-4 receptor alpha subunit (IL-4Rα) that blocks IL-4 and IL-13 signaling, two key drivers of type 2 inflammation. Herein, we review the mechanism of action and pharmacology of dupilumab, and the clinical evidence that led to the regulatory approvals of dupilumab for the treatment of numerous type 2 inflammatory diseases: atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis, eosinophilic esophagitis, and prurigo nodularis. (© 2024 Regeneron Pharmaceuticals, Inc and Sanofi. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.) |
| References: | Pharmacol Res Perspect. 2019 Dec;7(6):e00535. (PMID: 31859459) Nat Rev Drug Discov. 2023 Sep;22(9):743-767. (PMID: 37528191) Br J Dermatol. 2019 Nov;181(5):895-906. (PMID: 30758843) J Allergy Clin Immunol Pract. 2022 Nov;10(11):2916-2924.e4. (PMID: 36028446) J Allergy Clin Immunol. 2019 Jan;143(1):155-172. (PMID: 30194992) Clin Exp Allergy. 2021 Jul;51(7):915-931. (PMID: 34037993) J Allergy Clin Immunol Pract. 2022 Oct;10(10):2695-2709. (PMID: 35636689) Clin Pharmacol Ther. 1994 Sep;56(3):248-52. (PMID: 7924119) N Engl J Med. 2022 Dec 22;387(25):2317-2330. (PMID: 36546624) N Engl J Med. 2023 Jul 20;389(3):205-214. (PMID: 37272521) Lancet. 2017 Jun 10;389(10086):2287-2303. (PMID: 28478972) N Engl J Med. 2024 Jun 27;390(24):2274-2283. (PMID: 38767614) MAbs. 2013 Mar-Apr;5(2):297-305. (PMID: 23406896) J Pharmacokinet Pharmacodyn. 2001 Dec;28(6):507-32. (PMID: 11999290) Clin Transl Sci. 2024 Aug;17(8):e13899. (PMID: 39080841) Clin Pharmacol Drug Dev. 2020 Aug;9(6):742-755. (PMID: 32348036) Allergy. 2020 May;75(5):1188-1204. (PMID: 31838750) Nat Rev Drug Discov. 2016 Jan;15(1):35-50. (PMID: 26471366) Sci Transl Med. 2023 Dec 13;15(726):eadf9561. (PMID: 38091405) N Engl J Med. 2016 Dec 15;375(24):2335-2348. (PMID: 27690741) Nat Rev Drug Discov. 2023 Aug;22(8):662-680. (PMID: 37443275) |
| المشرفين على المادة: | 420K487FSG (dupilumab) 0 (Antibodies, Monoclonal, Humanized) 0 (Interleukin-4 Receptor alpha Subunit) 0 (Interleukin-13) 207137-56-2 (Interleukin-4) 0 (IL4R protein, human) 0 (IL4 protein, human) |
| تواريخ الأحداث: | Date Created: 20240731 Date Completed: 20240731 Latest Revision: 20240802 |
| رمز التحديث: | 20240802 |
| مُعرف محوري في PubMed: | PMC11288895 |
| DOI: | 10.1111/cts.13899 |
| PMID: | 39080841 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1752-8062 |
|---|---|
| DOI: | 10.1111/cts.13899 |